Bispecific T-Cell Engagers Market Report 2025

The bispecific T-cell engagers market size has grown exponentially in recent years. It will grow from $1.31 billion in 2024 to $1.6 billion in 2025 at a compound annual growth rate (CAGR) of 21.6%. The growth in the historic period can be attributed to increasing clinical trial activity, expanding momentum in regulatory approvals, rising prevalence and diagnosis of target cancers, growing interest in immuno-oncology combination therapies, and ongoing advances in antibody engineering and platform technologies.

The bispecific T-cell engagers market size is expected to see exponential growth in the next few years. It will grow to $3.45 billion in 2029 at a compound annual growth rate (CAGR) of 21.2%. The growth in the forecast period can be attributed to increasing investment in biomarker and companion diagnostic development, rising adoption in hematologic malignancies, growing interest in solid tumor applications, heightened patient and physician awareness, and expanding use in early-line therapies. Major trends during the forecast period include advancements in antibody engineering platforms, progress in immuno-oncology research, incorporation of bispecific antibodies into combination treatment regimens, integration of companion diagnostics for patient selection, and technological innovations in biomanufacturing.

The rising incidence of cancer is expected to drive growth in the bispecific T-cell engagers market in the coming years. Cancer, a group of diseases characterized by uncontrolled growth and spread of abnormal cells, can invade and damage healthy tissues. The increasing cancer burden is attributed to factors such as aging populations - where mutation accumulation over time raises risk - and unhealthy lifestyles, including smoking, poor diet, and physical inactivity. Bispecific T-cell engagers support cancer treatment by simultaneously binding to T cells and cancer cells, effectively bridging the immune system with tumor targets. This mechanism activates the patient’s T cells to recognize, attack, and kill malignant cells with high specificity. For instance, the World Health Organization (WHO) reported in February 2024 that the estimated 20 million new cancer cases in 2022 are projected to rise by 77%, reaching over 35 million cases by 2050.

Companies in the bispecific T-cell engagers market are developing advanced technologies to enhance targeted T-cell-mediated cancer therapy. One focus is improving cytolytic synapse formation, the process by which a T cell forms a specialized contact point with a tumor cell to deliver lethal signals that trigger tumor cell destruction. For example, in May 2024, Amgen Inc., a US-based biopharmaceutical company, launched IMDELLTRA (tarlatamab-dlle), the first FDA-approved DLL3-targeting bispecific T-cell engager therapy for extensive-stage small cell lung cancer (ES-SCLC). This therapy activates the patient’s T cells to attack DLL3-expressing tumor cells, providing a novel targeted immunotherapy option for patients whose disease progresses after platinum-based chemotherapy.

In March 2024, Merck & Co. Inc., a US-based pharmaceutical company, acquired Harpoon Therapeutics Inc. for an undisclosed amount. This acquisition strengthens Merck’s oncology pipeline by advancing innovative bispecific T-cell engager therapies to expand treatment options for patients with advanced cancers. Harpoon Therapeutics, a US-based clinical-stage immuno-oncology company, focuses on developing bispecific gamma-delta T-cell engagers for cancer therapy.

Major players in the bispecific t-cell engagers market are Pfizer Incorporated, Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Incorporated, Sanofi S.A., Amgen Incorporated, Regeneron Pharmaceuticals Incorporated, Ipsen S.A., Genmab A/S, Evotec SE, Akeso Inc., Immunocore Holdings Public Limited Company, MacroGenics Incorporated, Zymeworks Inc., Zenas BioPharma Limited, Candid Therapeutics Inc., BPS Bioscience Inc., Alloy Therapeutics Inc., AP Biosciences Inc., and Medigene AG.

North America was the largest region in the bispecific T-cell engagers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bispecific T-cell engagers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bispecific T-cell engagers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Bispecific T-cell engagers are a type of engineered antibody designed to simultaneously bind both T cells and cancer cells. By linking these two cell types, they redirect the immune system to more effectively recognize and eliminate tumor cells. This targeted mechanism of action positions them as a promising immunotherapy option, particularly for hematologic malignancies and certain solid tumors.

The primary types of bispecific T-cell engagers include monoclonal antibodies, bispecific antibodies, and others. Monoclonal antibodies (mAbs) are lab-engineered proteins that specifically bind to a single target antigen and are used to treat conditions such as cancer, autoimmune disorders, and infections by blocking harmful molecules or tagging them for immune destruction. Their applications include treatment of hematologic malignancies, solid tumors, and other conditions, and they serve various end users, including hospitals, specialty clinics, research institutes, and others.

The bispecific T-cell engagers market research report is one of a series of new reports that provides bispecific T-cell engagers market statistics, including the bispecific T-cell engagers industry global market size, regional shares, competitors with the bispecific T-cell engagers market share, detailed bispecific T-cell engagers market segments, market trends, and opportunities, and any further data you may need to thrive in the bispecific T-cell engagers industry. This bispecific T-cell engagers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bispecific T-cell engagers market consists of sales of solitomab, ebentafusp, glofitamab, epcoritamab, and mosunetuzumab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.